Table 2.
Prevalence (%) of the genomic signatures HRD-gLOH, TMB, MSI, PDL1, PDL2 and PD-L1+ protein expression
| Site | % HRD-gLOH | % TMB-H | % MSI-H | %PDL1 | %PDL2 | % PDL1 + | |
|---|---|---|---|---|---|---|---|
| ALL | local BC | 33.70% (2573/7636) | 5.04% (527/10464) | 0.37% (39/10464) | 1.57% (188/11988) | 1.53% (183/11988) | 54.25% (1092/2013) |
| BCBM | 52.01% (362/696) | 15.51% (116/748) | 2.01% (15/748) | 3.53% (29/822) | 3.41% (28/822) | 38.73% (55/142) | |
| N-CNS | 31.55% (3237/10260) | 9.82% (1395/14210) | 0.23% (32/14210) | 1.12% (174/15516) | 1.08% (168/15516) | 26.21% (615/2346) | |
| ER+/HER2− | local BC | 31.48% (119/378) | 3.41% (19/557) | 0.36% (2/557) | 0.94% (6/641) | 0.78% (5/641) | 40.00% (14/35) |
| BCBM | 43.17% (79/183) | 11.40% (22/193) | 1.04% (2/193) | 0.94% (2/212) | 0.47% (1/212) | 23.08% (9/39) | |
| N-CNS | 29.65% (126/425) | 8.92% (51/572) | 0.17% (1/572) | 0.32% (2/634) | 0.32% (2/634) | 12.99% (10/77) | |
| ER+/HER2+ | local BC | 19.57% (9/46) | 2.78% (2/72) | 0.00% (0/72) | 1.19% (1/84) | 1.19% (1/84) | 42.86% (3/7) |
| BCBM | 26.67% (16/60) | 9.68% (6/62) | 0.00% (0/62) | 1.52% (1/66) | 1.52% (1/66) | 27.27% (3/11) | |
| N-CNS | 47.37% (18/38) | 19.57% (9/46) | 0.00% (0/46) | 0.00% (0/49) | 0.00% (0/49) | 14.29% (1/7) | |
| ER−/HER2+ | local BC | 32.26% (10/31) | 8.70% (4/46) | 0.00% (0/46) | 1.75% (1/57) | 1.75% (1/57) | 100.00% (5/5) |
| BCBM | 33.33% (23/69) | 21.33% (16/75) | 2.67% (2/75) | 0.00% (0/85) | 0.00% (0/85) | 57.14% (4/7) | |
| N-CNS | 34.38% (11/32) | 4.26% (2/47) | 0.00% (0/47) | 3.92% (2/51) | 3.92% (2/51) | 42.86% (3/7) | |
| ER−/HER2− | local BC | 52.25% (186/356) | 2.70% (14/518) | 0.19% (1/518) | 3.42% (20/585) | 3.59% (21/585) | 50.00% (30/60) |
| BCBM | 70.45% (174/247) | 17.41% (47/270) | 2.59% (7/270) | 7.72% (23/298) | 7.72% (23/298) | 48.33% (29/60) | |
| N-CNS | 43.52% (84/193) | 10.04% (27/269) | 0.74% (2/269) | 3.78% (11/291) | 3.44% (10/291) | 21.43% (6/28) |
The significant alterations in brain metastases (BCBM) compared to local breast cancers (BC) are in bold letters. PDL1+ protein expression was lower in all the BMs compared to BCs except the ER-/HER2- BCBM subtype that is similar to BC and higher than non-central nervous system (N-CNS) metastases.